JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML
Histone demethylase JMJD3 is known to be oncogenic in preleukemic states and T-cell acute lymphocytic leukemia. Here, the authors show that in some acute myeloid leukemia subsets, JMJD3 can actually act as a potential oncorepressor via mediation of C/EBPβ-centered transcriptional programming.
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-05548-z |